Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 3/20 | 0.35 |
| ▸ | ARG2 | P78540 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849643 | 0.87 | PTPN1 (0.33) | ARG1ARG2THRB | |
| SCHEMBL1500318 | 0.84 | MEN1 (0.35) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL10575269 | 0.83 | MEN1 (0.31) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL11182469 | 0.82 | AKR1B1 (0.42) | MEN1ALDH1A1KMT2AFFAR1TDP1 | |
| SCHEMBL337746 | 0.80 | CES2 (0.45) | MEN1ALDH1A1KMT2AFFAR1TDP1 | |
| SCHEMBL337302 | 0.80 | CES2 (0.45) | MEN1ALDH1A1KMT2AFFAR1TDP1 | |
| SCHEMBL9708948 | 0.80 | CES2 (0.45) | MEN1ALDH1A1KMT2AFFAR1TDP1 | |
| SCHEMBL338379 | 0.80 | CES2 (0.45) | MEN1ALDH1A1KMT2AFFAR1TDP1 | |
| SCHEMBL5860198 | 0.80 | CES2 (0.45) | MEN1ALDH1A1KMT2AFFAR1TDP1 | |
| SCHEMBL7110479 | 0.80 | CES2 (0.45) | MEN1ALDH1A1KMT2AFFAR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160670-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL-2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | AVENTIS PHARMA S.A. (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20090163737-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL 2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | AVENTIS PHARMA S.A. (FR) | 2009-06-25 | — | — | US | disclosed |
| US-20080108847-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| EP-1578714-B1 | NOVEL CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS, METHOD AND INTERMEDIATE CHEMICALS FOR THE PREPARATION AND USE THEREOF FOR SYNTHESIS OF 2-(BROMOMETHYL)2-ETHYL HEXANOIC CHIRAL ACID | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1578714-A1 | NOVEL CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS, METHOD AND INTERMEDIATE CHEMICALS FOR THE PREPARATION AND USE THEREOF FOR SYNTHESIS OF 2-(BROMOMETHYL)2-ETHYL HEXANOIC CHIRAL ACID | Aventis Pharma S.A. (FR) | 2005-09-28 | — | — | EP | disclosed |
| US-20040147774-A1 | Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| WO-2004058678-A1 | NOVEL CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS, METHOD AND INTERMEDIATE CHEMICALS FOR THE PREPARATION AND USE THEREOF FOR SYNTHESIS OF 2-(BROMOMETHYL)2-ETHYL HEXANOIC CHIRAL ACID | AVENTIS PHARMA S.A (FR) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108847-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | HCAR2, HCAR3, HCAR1 | ARG1 2851/4885ARG2 2193/4885MEN1 4067/4885 |
| US-20090163737-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL 2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | HCAR3, HCAR2, HCAR1 | ARG1 2840/4885ARG2 3111/4885MEN1 4171/4885 |
| US-20040147774-A1 | Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid | HCAR2, FFAR2, HCAR3 | ARG1 2923/4885ARG2 3974/4885MEN1 3949/4885 |
| US-20100160670-A1 | NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL-2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID | HCAR2, HCAR3, HCAR1 | ARG1 2350/4885ARG2 2599/4885MEN1 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.